Eli Lilly Crushes Forecasts on Weight-Loss Drug Boom

Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.